Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Lower risk associated with SRS for brain mets shifts over time
Churilla T et al. JAMA Onc. 2018. doi: 10.1001/jamaoncol.2018.4610
Key clinical point: Stereotactic radiosurgery (SRS) provides better early local control of brain metastases than surgical resection, but this advantage fades with time.
Major finding: Patients treated with surgery were more likely to have local recurrence in the first 3 months following treatment, compared with patients treated with SRS (hazard ratio, 5.94).
Study details: An exploratory analysis of data from the European Organization for the Research and Treatment of Cancer (EORTC) 22952-26001 phase 3 trial. Analysis involved 268 patients with one to three brain metastases who underwent whole-brain radiotherapy or observation after SRS (n = 154) or complete surgical resection (n = 114).
Disclosures: The study was funded by the National Cancer Institute, National Institutes of Health, and Fonds Cancer in Belgium. Dr. Handorf reported financial compensation from Pfizer, via her institution.
Churilla T et al. JAMA Onc. 2018. doi: 10.1001/jamaoncol.2018.4610